Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND-JC: T Cell Therapy for PML
NCT05541549Phase 2Unknown
- Sponsor
- Cellevolve Bio
- Start
- Feb 2023
- Primary completion
- Mar 2024
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
01
Overview
Phase 2, randomised, double-blind trial in progressive multifocal leukoencephalopathy (PML) comparing CE-VST01-JC with Placebo (2 arms). Primary endpoint: Time to disease progression measured by modified Rankin Score at 1 year. Status: unknown.
02
Drugs
CE-VST01-JC
03
Conditions
progressive multifocal leukoencephalopathy (PML)
Beyond the preview
Go deeper on NCT05541549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05541549.